Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects

Despite the great success in the diagnosis and treatment of immuno-inflammatory rheumatic diseases (IIRD), which led to a significant improvement in the prognosis in many patients, the fundamental medical problems of this pathology – the restoration of quality of life and reduction of mortality to t...

Full description

Saved in:
Bibliographic Details
Main Authors: E. L. Nasonov, A. M. Lila
Format: Article
Language:Russian
Published: IMA PRESS LLC 2019-03-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/2668
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849400870703202304
author E. L. Nasonov
A. M. Lila
author_facet E. L. Nasonov
A. M. Lila
author_sort E. L. Nasonov
collection DOAJ
description Despite the great success in the diagnosis and treatment of immuno-inflammatory rheumatic diseases (IIRD), which led to a significant improvement in the prognosis in many patients, the fundamental medical problems of this pathology – the restoration of quality of life and reduction of mortality to the population level – are far from solution. This served as a powerful impetus to the study of new approaches to pharmacotherapy of IIRD, one of which is associated with the use of low-molecular synthetic drugs that inhibit intracellular "signal" molecules-Janus kinase (JAK), the socalled Jakinibs. The current achievements and trends concerning the use of JAK inhibitors in the treatment of IIRD are considered.
format Article
id doaj-art-c703663e1b4348ebbcf66b5e508eecd6
institution Kabale University
issn 1995-4484
1995-4492
language Russian
publishDate 2019-03-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj-art-c703663e1b4348ebbcf66b5e508eecd62025-08-20T03:37:53ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922019-03-0157181610.14412/1995-4484-2019-8-162443Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospectsE. L. Nasonov0A. M. Lila1Research Institute of Rheumatology; Department of Rheumatology, Institute of Professional Education, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaResearch Institute of RheumatologyDespite the great success in the diagnosis and treatment of immuno-inflammatory rheumatic diseases (IIRD), which led to a significant improvement in the prognosis in many patients, the fundamental medical problems of this pathology – the restoration of quality of life and reduction of mortality to the population level – are far from solution. This served as a powerful impetus to the study of new approaches to pharmacotherapy of IIRD, one of which is associated with the use of low-molecular synthetic drugs that inhibit intracellular "signal" molecules-Janus kinase (JAK), the socalled Jakinibs. The current achievements and trends concerning the use of JAK inhibitors in the treatment of IIRD are considered.https://rsp.mediar-press.net/rsp/article/view/2668immuno-inflammatory rheumatic diseasescytokinesjak inhibitorstofacitinib
spellingShingle E. L. Nasonov
A. M. Lila
Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects
Научно-практическая ревматология
immuno-inflammatory rheumatic diseases
cytokines
jak inhibitors
tofacitinib
title Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects
title_full Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects
title_fullStr Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects
title_full_unstemmed Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects
title_short Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects
title_sort janus kinase inhibitors in immuno inflammatory rheumatic diseases new opportunities and prospects
topic immuno-inflammatory rheumatic diseases
cytokines
jak inhibitors
tofacitinib
url https://rsp.mediar-press.net/rsp/article/view/2668
work_keys_str_mv AT elnasonov januskinaseinhibitorsinimmunoinflammatoryrheumaticdiseasesnewopportunitiesandprospects
AT amlila januskinaseinhibitorsinimmunoinflammatoryrheumaticdiseasesnewopportunitiesandprospects